<DOC>
	<DOCNO>NCT02229825</DOCNO>
	<brief_summary>Study assess efficacy Duloxetine 120 mg Duloxetine 60 mg patient hospitalize severe depression 4 week treatment . To evaluate rescue option non-responding patient . Safety Duloxetine also assess .</brief_summary>
	<brief_title>Study Assess Clinical Response Duloxetine Patients Hospitalized Severe Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . Male female patient 18 year age screen visit old 2 . Meet criterion severe Major Depressive Disorder ( MDD ) 3 . MontgomeryAsbergdepression rating scale ( MADRS ) total score ≥ 30 6item Hamilton Depression scale ( HAMD6 ) score ≥12 screening ( V1 ) visit baseline ( V2 ) visit 4 . Clinical Global Impression Severity ( CGISeverity ) score ≥4 screen visit baseline visit . 5 . Requirement hospitalization ( social nonmedical reason ) screen visit least Visit 4 6 . Patient willing able comply requirement hospitalization schedule visit , test procedure require protocol 7 . Have level understanding sufficient provide inform consent communicate investigator site personnel . Informed consent document must sign screen visit , accordance Good Clinical Practice ( GCP ) local regulatory requirement , prior study procedure 1 . More two previous episode major depression respond adequate dos duration ( minimum 6 week ) two different antidepressant therapy 2 . Lack response least two antidepressant therapy give adequate dos least 6 week current depressive episode 3 . Concurrent presence symptom fulfil criterion Axis I disorder anxiety disorder ( exception ObsessiveCompulsive Disorder ( OCD ) ) Major Depressive Disorder , investigator 's judgment 4 . Any previous diagnosis bipolar disorder , schizophrenia OCD 5 . Depression catatonic feature , depression postpartum onset , organic mental disorder 6 . The presence Axis II disorder 7 . MDD psychotic feature require neuroleptic treatment and/or interfere patient 's ability provide inform consent , investigator 's discretion 8 . History substance abuse dependence within past year , exclude nicotine caffeine , include alcohol benzodiazepine 9 . Positive urine screen drug abuse ( cannabinoids , cocaine , opiates include methadone , amphetamine ) screen 10 . Epilepsy history seizure disorder treatment anticonvulsant medication epilepsy seizures 11 . Patients acute liver injury ( hepatitis ) severe cirrhosis ( ChildPugh Class C ) 12 . Known diagnosis congenital galactosaemia , glucose galactose malabsorption syndrome , lactose deficiency 13 . Patient known diagnosis raise intraocular pressure , know risk acute narrowangle glaucoma 14 . Serious medical illness clinically significant laboratory abnormality , judgment investigator , likely require intervention/exclusion study medication course study : cardiovascular ( e.g . uncontrolled hypertension , abnormal initial ECG finding accord investigator judgement ) , respiratory , haematological , hepatic gastrointestinal 15 . End stage renal disease ( estimate creatinine clearance ≤30 mL/min ) undergo dialysis 16 . Abnormal thyroidstimulating hormone ( TSH ) concentration , base perform laboratory 's reference range . Patients must clinically chemically euthyroid time randomization . Patients may take thyroid replacement therapy provide dose stable compliance good least three month screen visit 17 . Pregnancy ( excluded urine pregnancy test screen visit ) breastfeed 18 . Sexually active woman childbearing potential ( i.e . 6 month postmenopausal , surgically sterilize ) use medically approve method birth control ( i.e . oral contraceptive , intrauterine device , doublebarrier ) least one month prior screen visit throughout study 19 . Participation another clinical trial within 30 day prior screen visit 20 . Current treatment Duloxetine indication previous treatment Duloxetine psychiatric indication 21 . Known hypersensitivity Duloxetine inactive ingredient 22 . History oversensitivity psychotropic drug , investigator 's judgment 23 . Electroconvulsive Therapy ( ECT ) Transcranial Magnetic Stimulation ( TMS ) within one year prior screen visit study 24 . Initiation discontinuation depressionoriented psychotherapeutic treatment ( e.g . behaviour therapy , psychoanalytic therapy , cognitive therapy , etc ) within 6 week prior screen visit , plan use treatment time study 25 . Treatment Monoamine Oxidase Inhibitor ( MAOI ) within 14 day prior baseline visit potential need use MAOI study within 5 day discontinuation duloxetine 26 . Treatment Fluoxetine within 30 day prior baseline visit 27 . Treatment exclude medication list protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>